Velicept scores $21 mln Series B

By Iris Dorbian — 2 months ago

Malvern, Pennsylvania-based Velicept Therapeutics, a clinical development company focused on advancing best-in-class medicines, has raised $21 million in Series B funding. CAM Capital and Longitude Capital led the round.

Continue

Allergan to buy VC-backed AqueSys for $300 mln

By Iris Dorbian — 5 months ago

Allergan plc has agreed to acquire Aliso Viejo, California-based medical device company AqueSys for $300 million upfront in cash. The deal is expected to close in the fourth quarter of this year. AqueSys’ backers include Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures and SV Life Sciences.

Continue

Orbus Therapeutics racks up $32.5 mln Series A

By Iris Dorbian — 6 months ago

Orbus Therapeutics Inc, a biopharmaceutical company focused on treating rare diseases, has closed $32.5 million in Series A funding. Longitude Capital, H.I.G. BioVentures and Adams Street Partners led the round. Also, the company has named Dr. Ernest Mario, an investor in this current round, as chairman of board.

Continue

VC-backed Aimmune Therapeutics goes public

By Iris Dorbian — 6 months ago

Brisbane, California-based Aimmune Therapeutics, a biopharmaceutical company focused on treating peanut allergies, has raised $160 million for its IPO after pricing its 10 million shares at $16 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “AIMT.” BofA Merrill Lynch, Credit Suisse and Piper Jaffray are serving as the lead underwriters. Aimmune’s backers include Longitude Capital, Foresite Capital and Aisling Capital.

Continue

Calhoun Vision nets $69 mln

By Iris Dorbian — 8 months ago

Calhoun Vision Inc, a provider of adjustable intraocular lens technology, has raised $69 million in funding. Longitude Capital led the round with participation from H.I.G. BioVentures, Balance Point Capital Partners and RA Capital Management.

Continue

Foresite Capital leads Series B round for Allergen Research Corp

By Iris Dorbian — 11 months ago

San Mateo, California-based Allergen Research Corp, which develops treatments for food allergies, has closed $80 million in Series B funding. Foresite Capital led the round with participation from Longitude Capital, Fidelity Management & Research Company, Aisling Capital, Adage Capital, RA Capital Management and Palo Alto Investors. In conjunction with the funding, Dr. Jim Tananbaum, CEO and managing director of Foresite Capital and Stacey Seltzer, a partner at Aisling Capital, have been added to ARC’s board of directors.

Continue

Longitude Capital, NovaQuest buy California Cryobank

By Luisa Beltran — 1 year ago

Longitude Capital and NovaQuest Capital Management have acquired California Cryobank. Financial terms weren’t announced. Los Angeles-based California Cryobank provides resources for frozen donor sperm and specialized reproductive services, including private egg and embryo storage services.

Continue

Collegium Pharmaceutical Raises $22.5M

By Staff Report — 4 years ago

Collegium Pharmaceutical Inc., a specialty pharmaceutical company focused on treatments for chronic pain, has raised $22.5 million in Series B financing. Longitude Capital and Skyline Ventures led the round. Series A investors Frazier Healthcare Ventures and Boston Millennia Partners also participated in the round. PRESS RELEASE Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on […]

Continue

Velomedix Seals $9.2M – Filing

4 years ago

Menlo Park, Calif.-based Velomedix Inc. has raised $9.3 million in combined equity and debt financing, according to a regulatory filing. The development stage medical device company is focusing on ways that mild therapeutic hypothermia can benefit patients suffering from cardiac arrest, heart attack, stroke and traumatic brain injury. Velomedix is backed by investors including Longitude Capital.

Continue

Slideshow: 15 Largest U.S.-based Venture Funds Raised in Q3

By Lawrence Aragon — 4 years ago

Q3 certainly wasn’t a pretty quarter for venture fundraising. In fact, it was downright ugly, with just $1.72 billion raised by 52 U.S.-based venture funds, the smallest amount raised since Q3 2003, according to the National Venture Capital Association and Thomson Reuters (publisher of peHUB). In contrast, 49 U.S.-based VC funds raised nearly $2.9 billion in […]

Continue

CardioDx Seals $60M in Equity Financing

5 years ago

CardioDx, a company developing cardiovascular genomic diagnostics, has raised $60 million in new equity funding. New investors Longitude Capital, J.P. Morgan, Acadia Woods Partners, Artiman Ventures, and Bright Capital, the venture arm of RU-COM, participated in the round, which also included the company’s previous investors. The company has raised money previously from Kleiner, Perkins, Caufield & Byers, Mohr Davidow Ventures, TPG Biotech, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group and GE Capital. Funding will be used to expand reimbursement coverage in the United States for the company’s blood-based gene expression test for obstructive coronary artery disease, as well as to continue development of future products. The company, based in Palo Alto, Calif., closed a $45 million round in May 2010.

Continue

PixelOptics Inks $45M Equity, Debt Round

5 years ago

Roanoke, Va.-based PixelOptics, the developer of electronic focusing eyeglasses, has closed $45 million in new financing. The round, led by publicly traded Safeguard Scientifics Inc., includes $35 million in equity and $10 million in venture debt. In addition to Safeguard Scientifics, Delphi Ventures, The Carlyle Group, Longitude Capital, and Stark Investments all contributed to the equity round. Horizon Technology Finance provided the venture debt funding. In 2008, peHub reported that the company had closed on $30 million in Series C financing from Longitude Capital, The Carlyle Group, Delphi Ventures, Stark Investments and Life Science Angels.

Continue

Civitas Therapeutics Gets $20M In Series A Financing

By Eamon — 5 years ago

Civitas Therapeutics Inc. secured $20 million for its Series A financing. Founding investor Longitude Capital, along with co-lead Canaan Partnersof Westport, Conn., participated in the round. Civitas is a Chelsea, Mass.-based biopharmaceutical company that develops transformative pulmonary delivery therapies. It plans to use proceeds to advance its lead program for treating patients with Parkinson’s disease through clinical proof-of-concept.

Continue

Aptus Endosystems Secures $15M Via Series AA Financing

By Eamon — 5 years ago

Aptus Endosystems Inc. completed a $15M Series AA financing. U.S. Venture Partners and Longitude Capital led the round. Aptus is a Sunnyvale, Calif.-based developer of technologies designed to treat aortic aneurysms. PRESS RELEASE Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), announced the completion of a $15 million […]

Continue